FNBT
NKTR icon

FineMark National Bank & Trust’s Nektar Therapeutics NKTR Stock Holding History

FineMark National Bank & Trust’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-600
Closed -$439K – 383
2018
Q2 		$439K Sell
600
-5
-0.8% -$5.76K 0.03% 272
2018
Q1 		$965K Buy
+605
New +$779K 0.06% 168

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

FineMark National Bank & Trust's NKTR Position: Q3 2018 in Review

FineMark National Bank & Trust sold out of Nektar Therapeutics (NKTR) in Q3 2018, closing a stake of 600 shares — an estimated $439K sold.

FineMark National Bank & Trust first reported a position in NKTR in Q1 2018 and held it in 2 quarters. The position peaked at $965K in Q1 2018. 389 funds tracked by Wall St. Rank hold NKTR as of Q3 2018.

  • FineMark National Bank & Trust reported no remaining Nektar Therapeutics position as of Q3 2018 after selling out during the quarter.
  • FineMark National Bank & Trust sold 600 Nektar Therapeutics shares in Q3 2018, an estimated $439K.
  • FineMark National Bank & Trust first reported a position in Nektar Therapeutics in Q1 2018 and held it in 2 quarters.
  • FineMark National Bank & Trust's Nektar Therapeutics position peaked at $965K in Q1 2018.
  • 389 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2018.

Based on FineMark National Bank & Trust's 13F filing for Q3 2018, filed 2 Nov 2018.